Japanese pharma giant Takeda Pharmaceutical (TYO: 4502) has entered a collaboration and license deal to develop in vivo novel adeno-associated viral (AAV) based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets, with privately-held US start-up StrideBio.
These programs aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system.
"We are very excited to partner with Takeda given their expertise and commitment to developing of StrideBio., adding: "We look forward to working together to bring transformative and novel AAV-based gene therapies to patients, while continuing to validate and expand StrideBio's platform, manufacturing capabilities and pipeline," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze